Table 2.

Summarized key features according to treatment option.

Treatment Option	No. of included Studies	No. P.	Size†‡	EHM%	CR/R0%	OS†	DFS†	Strength /Weakness
RFA	8	203	2–2.5 (0.5–5)	40–83	5–88	11–60	8–24	low morbidity, repeatability/insufficient local control in large tumors
CRA	1	17	3.5 (2–5)	NR	85	NR	NR	low morbidity/no long-term data, single center
SRFA	1	26	2 (0.4–8.5)†	46	92	29.3	31.6	low morbidity, good local tumor control in small and large tumors/single center
HR	24	1173	1.8–5.1 (0.4–19)	0–48	62–96	24–116	11–53	good local tumor control in small and large tumors/high morbidity, limited repeatability
SBRT	2	64	2.1/NR	32	88	22/NR	7.4/NR	low morbidity/high recurrence, short survival time
BT	1	41	4.6 (1.5–11)	NR	93.5	NR	NR	low morbidity/no long-term data, single center
SIRT	7	380	NR	6–89	0–5	4–14	3.2/NR	low morbidity/palliative
TACE	2	71	2.8 (1–8)/NR	40–49	2–7	10–28	3.3/NR	low morbidity/ palliative

Tr. = local treatment, No. P. = number of patients, No. T. T/$\overline{x}$/%s = number of tumors, total number/mean/% solitary, EHM = extrahepatic metastases, $\tilde{x}$, † = median, $\overline{x}$, ‡ = mean, FU = follow-up, HR = hepatic resection, RFA = radiofrequency ablation, SRFA = stereotactic radiofrequency ablation, SBRT = stereotactic body radiation therapy, TACE = transarterial chemoembolization, BT = brachytherapy, CRA = cryoablation.